ENDOTHELIN IN HUMANS CORONARY IN EARLY ATHEROSCLEROSIS

Summary

Principal Investigator: AMIR contact LERMAN
Abstract: DESCRIPTION (Adapted from the application): The current application serves as a natural extension of the principal investigator's previous KO-8, which focused on endothelin in the coronary circulation in humans. Previous studies have focused on the vasodilator and its contribution to the development of coronary atherosclerosis. However, there is a void of information about the role of the endothelium-derived vasoconstrictor factors in the early stages of the disease state. A growing body of evidence suggests that endothelin plays a significant role in the regulation of vascular tone under normal conditions and in pathophysiological states. The PI's broad working hypothesis is that in early atherosclerosis the activity of the endogenous coronary endothelin system is enhanced and is associated with coronary artery disease risk factors. Moreover, administration of chronic endothelin receptor antagonist in this patient population will improve coronary endothelial function. This improvement of coronary endothelial function will result in restoration of myocardial perfusion, which is impaired in early atherosclerosis with coronary endothelial dysfunction. These beneficial effects are partially mediated by the enhancement of the endogenous coronary nitric oxide system. To address the PI's working hypothesis, three Specific Aims are proposed: Aim I: To determine the activity of the endogenous endothelin system in the coronary circulation in humans with coronary endothelial dysfunction and atherosclerosis risk factors. Aims II: To assess the potential of chronic endothelin receptor antagonists to improve preexisting coronary endothelial dysfunction and myocardial perfusion in humans and Aim III: To assess the effect of chronic endothelin receptor antagonism on the endogenous nitric oxide system in humans with early coronary atherosclerosis. The studies will be performed in patients with coronary endothelial dysfunction and coronary artery disease risk factors. Coronary endothelin, big endothelial and nitric oxide will be measured and myocardial perfusion will be assessed with SPECT. The patients with endothelial dysfunction will be randomized to chronic administration of an endothelin receptor antagonist. Coronary endothelial function and myocardial perfusion will be assessed at six-month follow up. The activity of endothelin also will be assessed in human vessels in vitro and immunohistochemistry will be performed. The functional interaction between endothelin and the nitric oxide pathway also will be addressed in vivo in humans by assessing the physiological response to the acute inhibition of nitric generation and also assessing NO production. The current application will contribute to our understanding of the role of the endogenous endothelin in modulating endothelial function in early coronary atherosclerosis in humans and may have a significant therapeutic potential for this disease process.
Funding Period: 2000-07-01 - 2006-06-30
more information: NIH RePORT

Top Publications

  1. ncbi Coronary endothelial dysfunction and hyperlipidemia are independently associated with diastolic dysfunction in humans
    Ahmad A Elesber
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Am Heart J 153:1081-7. 2007
  2. pmc Primary proteasome inhibition results in cardiac dysfunction
    Joerg Herrmann
    Division of Cardiovascular Diseases, Mayo Clinic Rochester, 200 First Street, SW, Rochester, MN 55905, USA
    Eur J Heart Fail 15:614-23. 2013
  3. pmc Association of plaque composition and vessel remodeling in atherosclerotic renal artery stenosis: a comparison with coronary artery disease
    Tetsuro Kataoka
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    JACC Cardiovasc Imaging 2:327-38. 2009
  4. pmc Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect
    Dallit Mannheim
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Atherosclerosis 216:283-91. 2011
  5. pmc Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis
    Martin Reriani
    Division of Cardiovascular Diseases, Mayo Clinic Rochester, 200 First St SW, Rochester, MN 55905, USA
    Circulation 122:958-66. 2010
  6. pmc Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress
    Adi R Bachar
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Cardiovasc Res 88:360-6. 2010
  7. pmc Coronary microcirculatory vasodilator function in relation to risk factors among patients without obstructive coronary disease and low to intermediate Framingham score
    Ronen Rubinshtein
    Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, MB 4 523, 200 First Street SW, Rochester, MN 55905, USA
    Eur Heart J 31:936-42. 2010
  8. pmc Coronary artery endothelial dysfunction is positively correlated with low density lipoprotein and inversely correlated with high density lipoprotein subclass particles measured by nuclear magnetic resonance spectroscopy
    Monique A Ford
    Division of Cardiovascular Diseases, Mayo Clinic Rochester, United States
    Atherosclerosis 207:111-5. 2009
  9. pmc Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients
    Eugenia Raichlin
    William J von Liebig Transplant Center, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Transplantation 85:963-8. 2008
  10. ncbi Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques
    Dallit Mannheim
    Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Stroke 39:1448-55. 2008

Scientific Experts

  • AMIR contact LERMAN
  • Joerg Herrmann
  • Claudio Napoli
  • Lilach O Lerman
  • Abhiram Prasad
  • Shahar Lavi
  • Charanjit S Rihal
  • Verghese Mathew
  • Dallit Mannheim
  • Ahmad A Elesber
  • Mario Gossl
  • Joseph P McConnell
  • Offer Galili
  • Daniele Versari
  • Ryan J Lennon
  • Eric H Yang
  • Eugenia Raichlin
  • David R Holmes
  • Katherine J E Sattler
  • Ronen Rubinshtein
  • Ryan Lennon
  • Rebecca E Nelson
  • Jang Ho Bae
  • Fredric B Meyer
  • Alejandro R Chade
  • Adi R Bachar
  • Martin Reriani
  • Ronit Lavi
  • Geralyn M Pumper
  • S Lavi
  • Andrew Cassar
  • Tetsuro Kataoka
  • Monique A Ford
  • Piero O Bonetti
  • Erik L Ritman
  • Gregory W Barsness
  • R J Lennon
  • Robert H Nelson
  • Katherine J Sattler
  • A R Chade
  • Xiang Yang Zhu
  • James D Krier
  • Julie E Woodrum
  • David Brosh
  • Monica Olson
  • Lea Scheffer
  • Yun K Oh
  • Pinchas Cohen
  • Richard E Pagano
  • Andreas S Schroeder
  • Giuseppe Sangiorgi
  • Heike A Hildebrandt
  • Raimund Erbel
  • Thomas Bajanowski
  • Patricia J Best
  • Laura J Cobb
  • Hiromi K Nakamura
  • Charanjit Rihal
  • Stacy J Hartman
  • D R Holmes
  • J H Bae
  • G W Barsness
  • A Prasad
  • Gurpreet S Sandhu
  • Panithaya Chareonthaitawee
  • C S Rihal
  • Walter K Kremers
  • Sundeep Khosla
  • Elizabeth J Atkinson
  • Bailey Kent
  • Gregory D Novak
  • Ulrike I Mödder
  • Robert P Frantz
  • Holmes R David
  • Amir Ali Fassa
  • Monica L Olson
  • Vincent S Rajkumar
  • Ahmad Elesber
  • John M Miles
  • Margaret M Redfield
  • Elena Daghini
  • Robert D Simari
  • Alejandro Chade
  • Michael T Overgaard
  • Brooks S Edwards
  • Katherine Sattler
  • Steven G Younkin
  • Claus Oxvig
  • Sudhir S Kushwaha
  • Michael Christiansen

Detail Information

Publications45

  1. ncbi Coronary endothelial dysfunction and hyperlipidemia are independently associated with diastolic dysfunction in humans
    Ahmad A Elesber
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Am Heart J 153:1081-7. 2007
    ..The objective of the this study was to determine if CED and CAD factors are associated with diastolic dysfunction before the development of occlusive CAD or clinical heart failure...
  2. pmc Primary proteasome inhibition results in cardiac dysfunction
    Joerg Herrmann
    Division of Cardiovascular Diseases, Mayo Clinic Rochester, 200 First Street, SW, Rochester, MN 55905, USA
    Eur J Heart Fail 15:614-23. 2013
    ..Utilizing the same model, this study was designed to test the hypothesis that chronic proteasome inhibition (PSI) also leads to structural and functional changes of the heart...
  3. pmc Association of plaque composition and vessel remodeling in atherosclerotic renal artery stenosis: a comparison with coronary artery disease
    Tetsuro Kataoka
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    JACC Cardiovasc Imaging 2:327-38. 2009
    ..The current study was designed to investigate the relationship between renal arterial structure and vessel remodeling in patients with atherosclerotic renal artery stenosis (RAS), compared with that seen in coronary artery disease (CAD)...
  4. pmc Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect
    Dallit Mannheim
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Atherosclerosis 216:283-91. 2011
    ..It has been attributed to myocardial fibrosis and related to cardiovascular risk factor exposure. We hypothesized that simvastatin will improve these dynamics in experimental hypercholesterolemia (HC)...
  5. pmc Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis
    Martin Reriani
    Division of Cardiovascular Diseases, Mayo Clinic Rochester, 200 First St SW, Rochester, MN 55905, USA
    Circulation 122:958-66. 2010
    ..The present study was designed to test the hypothesis that long-term treatment with an endothelin-A (ET(A)) receptor antagonist improves coronary endothelial function in patients with early coronary atherosclerosis...
  6. pmc Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress
    Adi R Bachar
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Cardiovasc Res 88:360-6. 2010
    ..The current study was designed to test the hypothesis that HN is expressed in the human vascular wall and may protect against oxidative stress...
  7. pmc Coronary microcirculatory vasodilator function in relation to risk factors among patients without obstructive coronary disease and low to intermediate Framingham score
    Ronen Rubinshtein
    Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, MB 4 523, 200 First Street SW, Rochester, MN 55905, USA
    Eur Heart J 31:936-42. 2010
    ..The study aim was to evaluate the relation between the Framingham risk score (FRS) and the presence of coronary risk factors to coronary microcirculatory vasodilator function in patients with early coronary atherosclerosis...
  8. pmc Coronary artery endothelial dysfunction is positively correlated with low density lipoprotein and inversely correlated with high density lipoprotein subclass particles measured by nuclear magnetic resonance spectroscopy
    Monique A Ford
    Division of Cardiovascular Diseases, Mayo Clinic Rochester, United States
    Atherosclerosis 207:111-5. 2009
    ..The association between cholesterol and endothelial dysfunction remains controversial. We tested the hypothesis that lipoprotein subclasses are associated with coronary endothelial dysfunction...
  9. pmc Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients
    Eugenia Raichlin
    William J von Liebig Transplant Center, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Transplantation 85:963-8. 2008
    ..We evaluated the association between Lp-PLA2, cardiac allograft vasculopathy (CAV) assessed by 3D intravascular ultrasound, and incidence of cardiac adverse events in heart transplant recipients...
  10. ncbi Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques
    Dallit Mannheim
    Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Stroke 39:1448-55. 2008
    ..Therefore, this study was performed to test the hypothesis that Lp-PLA(2) expression is higher in symptomatic than in asymptomatic carotid plaques of patients undergoing carotid endarterectomy...
  11. ncbi Association between the paraoxonase-1 192Q>R allelic variant and coronary endothelial dysfunction in patients with early coronary artery disease
    Shahar Lavi
    Division of Cardiovascular Diseases, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:158-64. 2008
    ..To test the hypothesis that allelic variants of the paraoxonase-1 gene are associated with endothelial dysfunction, an early stage of atherosclerosis...
  12. ncbi The interaction between coronary endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in humans
    Shahar Lavi
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minn 55905, USA
    Hypertension 51:127-33. 2008
    ..This study supports the hypothesis that local oxidative stress has a role in reduction of NO bioavailability in humans with coronary endothelial dysfunction...
  13. ncbi The effect of drug eluting stents on cardiovascular events in patients with intermediate lesions and borderline fractional flow reserve
    Shahar Lavi
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Catheter Cardiovasc Interv 70:525-31. 2007
    ..To assess the role of fractional flow reserve (FFR) in guiding therapy in the drug eluting stent (DES) era...
  14. ncbi Chronic proteasome inhibition contributes to coronary atherosclerosis
    Joerg Herrmann
    Division of Cardiovascular Diseases, Mayo Clinic and College of Medicine, Rochester, MN 55905, USA
    Circ Res 101:865-74. 2007
    ..These findings support the significance of the proteasome and related protein quality control for vascular biology and pathology...
  15. ncbi Potential role of the ubiquitin-proteasome system in atherosclerosis: aspects of a protein quality disease
    Joerg Herrmann
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 51:2003-10. 2008
    ..This review summarizes these recent findings with a focus on atherosclerosis. In particular, this paper reflects on the viewpoint of atherosclerosis as a protein quality disease...
  16. pmc Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis
    Eugenia Raichlin
    Division of Cardiovascular Diseases, Center for Coronary Physiology and Imaging, Mayo Clinic, Rochester, MN 55905, USA
    Hypertension 52:522-8. 2008
    ..These findings suggest the beneficial role of atrasentan in the treatment of hypertension and metabolic syndrome...
  17. pmc Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis
    Mario Gossl
    Division of Cardiology, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 52:1314-25. 2008
    ..This study was designed to test whether patients with coronary atherosclerosis have increases in circulating endothelial progenitor cells (EPCs) expressing an osteogenic phenotype...
  18. ncbi Segmental coronary endothelial dysfunction in patients with minimal atherosclerosis is associated with necrotic core plaques
    S Lavi
    Division of Cardiovascular Diseases and the Center for Coronary Physiology and Imaging, Mayo Clinic, Rochester, MN 55905, USA
    Heart 95:1525-30. 2009
    ..This study was designed to test the hypothesis that in patients with minimal coronary atherosclerosis, coronary artery segments with abnormal endothelial function have specific plaque characteristics...
  19. pmc Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome
    Joerg Herrmann
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Eur Heart J 30:2930-8. 2009
    ..The aim was to test the hypothesis that carotid artery plaque expression of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) predicts cardiac events...
  20. pmc On to the road to degradation: atherosclerosis and the proteasome
    Joerg Herrmann
    Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Cardiovasc Res 85:291-302. 2010
    ..It will conclude with the integration of the available information in a synoptic view of the involvement of the UPS in atherosclerosis...
  21. pmc Lack of correlation between noninvasive stress tests and invasive coronary vasomotor dysfunction in patients with nonobstructive coronary artery disease
    Andrew Cassar
    Department of Internal Medicine, Mayo College of Medicine, Rochester, MN 55905, USA
    Circ Cardiovasc Interv 2:237-44. 2009
    ..The ability of noninvasive stress tests to predict coronary vasomotor dysfunction in patients with nonobstructive coronary artery disease is unknown...
  22. pmc Segmental heterogeneity of vasa vasorum neovascularization in human coronary atherosclerosis
    Mario Gossl
    Division of Cardiovascular Diseases, Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    JACC Cardiovasc Imaging 3:32-40. 2010
    ..Our aim was to investigate the role of coronary vasa vasorum (VV) neovascularization in the progression and complications of human coronary atherosclerotic plaques...
  23. ncbi Atherosclerosis in the back yard
    Joerg Herrmann
    Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 49:2102-4. 2007
    ..In the current focus issue of the Journal, 4 articles and this commentary are devoted to this topic...
  24. ncbi Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans
    Shahar Lavi
    Division of Cardiovascular Diseases, Mayo Clinic, Mary Brigh 4 523, First ST SW, Rochester, MN 55905, USA
    Circulation 115:2715-21. 2007
    ..Inflammation also is associated with coronary atherosclerosis. We tested the hypothesis that local coronary production of Lp-PLA2 is enhanced in patients with early coronary atherosclerosis and associated with local endothelial function...
  25. ncbi Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis
    Ahmad A Elesber
    Division of Cardiovascular Disease, Nephrology, and Internal Medicine, Mayo College of Medicine, Rochester, MN 55905, USA
    Eur Heart J 27:824-31. 2006
    ....
  26. ncbi Mild renal insufficiency is associated with reduced coronary flow in patients with non-obstructive coronary artery disease
    A R Chade
    Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota 55902, USA
    Kidney Int 69:266-71. 2006
    ..Impairment in both microcirculatory beds may reflect an unmeasured risk factor induced by blunted renal function and add a burden to the increased propensity for cardiovascular events in CKD...
  27. ncbi Dietary reversal of experimental hypercholesterolemia improves endothelial dysfunction of epicardial arteries but not of small coronary vessels in pigs
    Katherine J E Sattler
    Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN, USA
    Atherosclerosis 188:301-8. 2006
    ..Hence, dietary normalization of serum lipid levels alone may not be synonymous to normalization of the components of endothelial dysfunction...
  28. ncbi Management of the patient with chest pain and a normal coronary angiogram
    Eric H Yang
    The Center of Coronary Physiology and Imaging, Division of Cardiovascular Diseases, Mayo College of Medicine, Rochester, MN 55905, USA
    Cardiol Clin 23:559-68, viii. 2005
  29. ncbi Effect of lesion length on fractional flow reserve in intermediate coronary lesions
    David Brosh
    Cardiovascular Division, Mayo Clinic Foundation, Rochester, MN 55902, USA
    Am Heart J 150:338-43. 2005
    ..However, the effect of LL on FFR has not been adequately assessed. We sought to evaluate the effect of LL on FFR in patients with angiographically intermediate coronary artery disease...
  30. ncbi Bosentan preserves endothelial function in mice overexpressing APP
    Ahmad A Elesber
    Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurobiol Aging 27:446-50. 2006
    ..The current study demonstrates the presence of endothelial dysfunction in both carotid and aortic arteries in mice overexpressing APP and suggests a pathophysiological role for the endogenous endothelin system in AD...
  31. ncbi Experimental hypercholesterolemia differentially affects adventitial vasa vasorum and vessel structure of the left internal thoracic and coronary arteries
    Offer Galili
    Division of Cardiovascular Diseases, Mayo College of Medicine, Rochester, MN 55905, USA
    J Thorac Cardiovasc Surg 129:767-72. 2005
    ..Hence the current study was designed to characterize and compare the structure of the adventitial vasa vasorum in the left internal thoracic and coronary arteries...
  32. ncbi Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia
    Alejandro R Chade
    Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Am Soc Nephrol 16:1005-12. 2005
    ..This study may support a role for the ubiquitin/proteasome system in the kidney in HC and early atherosclerosis...
  33. ncbi Endothelial function: cardiac events
    Amir Lerman
    Division of Cardiovascular Disease and Department of Internal Medicine, Mayo College of Medicine, 200 First St SW, Rochester, MN 55902, USA
    Circulation 111:363-8. 2005
  34. ncbi Women and cardiovascular heart disease: clinical implications from the Women's Ischemia Syndrome Evaluation (WISE) Study. Are we smarter?
    Amir Lerman
    Division of Cardiovascular Disease and Department of Internal Medicine, Mayo College of Medicine, Rochester, Minnesota 55902, USA
    J Am Coll Cardiol 47:S59-62. 2006
    ..It may be advantageous to add such diagnostic tests when the conventional tests are nondiagnostic. A revised clinical approach to cardiovascular disease in women may be designed and tested based on these findings...
  35. ncbi Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina
    Ahmad A Elesber
    Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Eur Heart J 27:1678-84. 2006
    ....
  36. ncbi Ubiquitin and ubiquitin-like proteins in protein regulation
    Joerg Herrmann
    Division of Cardiovascular Diseases, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Circ Res 100:1276-91. 2007
    ..This review provides an overview of this class of molecules and its implication for function, subcellular location, and half-life of proteins...
  37. ncbi Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease
    Shahar Lavi
    Division of Cardiovascular Diseases, Mayo College of Medicine, Rochester, MN 55905, USA
    Circulation 115:2621-7. 2007
    ..The present study was designed to test the hypothesis that smoking is associated with epicardial coronary endothelial dysfunction and inflammation...
  38. ncbi Myocardial uptake of circulating triglycerides in nondiabetic patients with heart disease
    Robert H Nelson
    Endocrine Research Unit, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Diabetes 56:527-30. 2007
    ..5%). These results indicate that circulating triglycerides may be a significant source of fatty acids for myocardial respiration...
  39. ncbi Impaired myocardial perfusion reserve in experimental hypercholesterolemia is independent of myocardial neovascularization
    Dallit Mannheim
    Division of Cardiovascular Diseases, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Am J Physiol Heart Circ Physiol 292:H2449-58. 2007
    ..This suggests that the myocardial neovascularization may not contribute to the attenuated myocardial perfusion response in hypercholesterolemia...
  40. ncbi Rethinking primary prevention of atherosclerosis-related diseases
    Claudio Napoli
    Department of General Pathology and Excellence Research Center on Cardiovascular Diseases, 1st School of Medicine, II University of Naples, Complesso S Andrea delle Dame, Naples 80134, Italy
    Circulation 114:2517-27. 2006
  41. ncbi Association of angiotensin-converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy
    Jang Ho Bae
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Transplantation 82:1108-11. 2006
    ..In conclusion, plaque progression is associated with positive vascular remodeling and plaque regression is associated with lower serum lipids and ACEI in patients after TX...
  42. ncbi Early experimental obesity is associated with coronary endothelial dysfunction and oxidative stress
    Offer Galili
    Department of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Am J Physiol Heart Circ Physiol 292:H904-11. 2007
    ..Vascular dysfunction is therefore an early manifestation of obesity and might contribute to the increased cardiovascular risk, independently of insulin resistance...
  43. ncbi Angiogenesis in atherogenesis
    Joerg Herrmann
    Division of Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Arterioscler Thromb Vasc Biol 26:1948-57. 2006
    ..This article gives an updated overview on this topic and briefly reflects on the similarities with neovessel formation in carcinogenesis...
  44. ncbi Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis
    Daniele Versari
    Division of Cardiovascular Diseases, Mayo Clinic Rochester, 200 First St SW, Rochester, MN 55905, USA
    Arterioscler Thromb Vasc Biol 26:2132-9. 2006
    ..The aim of this study was to evaluate the activity of ubiquitin-proteasome system in human carotid artery plaques in relation to oxidative stress and clinical manifestation...
  45. ncbi Concurrent treatment with renin-angiotensin system blockers and acetylsalicylic acid reduces nuclear factor kappaB activation and C-reactive protein expression in human carotid artery plaques
    Katherine J E Sattler
    Division of Cardiovascular Diseases, Mayo Clinic Rochester, Rochester, Minn 55905, USA
    Stroke 36:14-20. 2005
    ..We hypothesized that the combination of RAS blockers (RASb) and ASA reduces NFkappaB and CRP within atherosclerotic plaques...